The neurofeedback device uses electroencephalography (EEG) to record a patients' brainwaves. Via certain algorithms, the device triggers particular brainwave entertainment in the form of sound - known as binaural beats - to relax the brain, improve attention, and reduce anxiety, depression and chronic pain in children/adults with autistic traits. This allows patients to follow instructions or to stay focused more easily since it lowers the high levels of delta and theta brainwaves and reduces excessive high beta waves. The headband thus includes a set of ear phones that the user needs to also wear. Each therapy session lasts around 40 minutes each. The device is connected to a software application that allows the professional therapists and parents to record and view the patient sessions so as to monitor progress.
The device has been available on the market since 2019. The company is seeking agents/distributors that have connections with healthcare professionals/clinics/hospitals that help autism patients to enter into distribution agreements.
The algorithm and software can be modified to cater for other conditions such as ADHD and depression. For this reason, to be able to further their R&D and extend their portfolio of devices, the company is also seeking investors who are willing to enter into financial agreements.
Advantages & innovations
The headband is CE Certified and classified as a Grade IIA medical device. The company that developed is ISO 13485 certified. The device is easy to wear, comfortable, portable and lightweight. The device is connected to a software application to monitor therapy sessions.
The algorithm and software program can be modified to different binaural beats to cater for other neuro-related conditions such as ADHD and depression.
Stage of development
Already on the market
Partner sought
Agent/distributor that have connections with healthcare professionals/clinics/hospitals that support patients with autism.
Investors that are interested to enter into financial agreements for the company to be able to invest in further R&D to be able to extend its portfolio of products.